drugsTreatmentPhase 2

EB-MF-CAR-NK-01

aka Mesothelin/FAP Dual-Target CAR-NK Cells

EB-MF-CAR-NK-01 is an experimental bispecific antibody from Beijing Biotech in phase 2 trials for mesothelioma, aimed at Mesothelin and FAP.

EB-MF-CAR-NK-01 is a bispecific antibody developed by Beijing Biotech. Its targets are Mesothelin and FAP. ClinicalTrials.gov describes the intervention as: Example investigational product: donor-derived allogeneic NK cells engineered to recognize both MSLN-positive tumour cells and FAPpositive stromal elements, manufactured under GMP. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in mesothelioma. The largest, NCT07510815, plans to enrol 36 participants with primary completion expected 2027-03-14. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How it works, step by step · animated schematic, not to scale; chosen from the modality "bispecific antibody"

Bispecific antibodies →

Modality

bispecific antibody

Mechanism

Bispecific antibody directed at Mesothelin and FAP, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

EB-MF-CAR-NK-01

intervention: EB-MF-CAR-NK-01

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.